Related Articles
A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer
Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage III colorectal cancer
Feasibility of oral administration of S-1 as adjuvant chemotherapy in gastric cancer: 4-week S‑1 administration followed by 2-week rest vs. 2-week administration followed by 1-week rest
Feasibility and early outcome of high-dose-rate Ir-192 brachytherapy as monotherapy in two fractions within 1 day for high-/very high-risk prostate cancer
Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer